dc.contributor.author | Della Vittoria Scarpati, Giuseppina | en_US |
dc.contributor.author | Fusciello, Celeste | en_US |
dc.contributor.author | Perri, Francesco | en_US |
dc.contributor.author | Sabbatino, Francesco | en_US |
dc.contributor.author | Ferrone, Soldano | en_US |
dc.contributor.author | Carlomagno, Chiara | en_US |
dc.contributor.author | Pepe, Stefano | en_US |
dc.date.accessioned | 2014-03-11T13:53:49Z | |
dc.date.issued | 2014 | en_US |
dc.identifier.citation | Della Vittoria Scarpati, Giuseppina, Celeste Fusciello, Francesco Perri, Francesco Sabbatino, Soldano Ferrone, Chiara Carlomagno, and Stefano Pepe. 2014. “Ipilimumab in the treatment of metastatic melanoma: management of adverse events.” OncoTargets and therapy 7 (1): 203-209. doi:10.2147/OTT.S57335. http://dx.doi.org/10.2147/OTT.S57335. | en |
dc.identifier.issn | 1178-6930 | en |
dc.identifier.uri | http://nrs.harvard.edu/urn-3:HUL.InstRepos:11879891 | |
dc.description.abstract | Recently, “ipilimumab,” an anti-cytotoxic T-lymphocyte antigen-4 (CTLA-4) monoclonal antibody, has been demonstrated to improve overall survival in metastatic melanoma. “CTLA-4” is an immune-checkpoint molecule that downregulates pathways of T-cell activation. Ipilimumab, by targeting CTLA-4, is able to remove the CTLA-4 inhibitory signal, allowing the immune system to react to cancer cells. Due to its immune-based mechanism of action, ipilimumab causes the inhibition of CTLA-4-mediated immunomodulatory effects, the enhancement of antitumor specific immune response mediated by the weakening of self-tolerance mechanisms while exacerbating the development of autoimmune diseases and immune-related adverse events, including dermatitis, hepatitis, enterocolitis, hypophysitis, and uveitis. | en |
dc.language.iso | en_US | en |
dc.publisher | Dove Medical Press | en |
dc.relation.isversionof | doi:10.2147/OTT.S57335 | en |
dc.relation.hasversion | http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3933725/pdf/ | en |
dash.license | LAA | en_US |
dc.subject | melanoma | en |
dc.subject | T-cells | en |
dc.subject | CTLA-4 | en |
dc.subject | autoimmunity | en |
dc.subject | adverse events | en |
dc.title | Ipilimumab in the treatment of metastatic melanoma: management of adverse events | en |
dc.type | Journal Article | en_US |
dc.description.version | Version of Record | en |
dc.relation.journal | OncoTargets and therapy | en |
dash.depositing.author | Sabbatino, Francesco | en_US |
dc.date.available | 2014-03-11T13:53:49Z | |
dc.identifier.doi | 10.2147/OTT.S57335 | * |
dash.contributor.affiliated | Ferrone, Soldano | |
dash.contributor.affiliated | Sabbatino, Francesco | |